• LAST PRICE
    7.9950
  • TODAY'S CHANGE (%)
    Trending Down-0.1650 (-2.0221%)
  • Bid / Lots
    7.9900/ 4
  • Ask / Lots
    8.0000/ 10
  • Open / Previous Close
    8.0500 / 8.1600
  • Day Range
    Low 7.9500
    High 8.1900
  • 52 Week Range
    Low 5.4200
    High 18.7300
  • Volume
    498,682
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 8.16
TimeVolumeIOVA
09:32 ET812708.17
09:33 ET166818.15
09:35 ET238768.06
09:37 ET37558.09
09:39 ET304308.045
09:42 ET396337.9877
09:44 ET240478
09:46 ET183878.0425
09:48 ET159618.07
09:50 ET180548.05
09:51 ET210087.99
09:53 ET127788.01
09:55 ET177868
09:57 ET194958
10:00 ET91127.9987
10:02 ET259607.99
10:04 ET142807.97
10:06 ET402598.01
10:08 ET80967.995
10:09 ET32327.995
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIOVA
Iovance Biotherapeutics Inc
1.3B
-3.2x
---
United StatesGERN
Geron Corp
1.3B
-9.3x
---
United StatesCINC
CinCor Pharma Inc
1.3B
-12.2x
---
United StatesNAMS
NewAmsterdam Pharma Company NV
1.3B
-78.4x
---
United StatesZNTL
Zentalis Pharmaceuticals Inc
1.3B
-5.0x
---
United StatesSAVA
Cassava Sciences Inc
1.2B
-15.9x
---
As of 2023-01-30

Company Information

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). It is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Contact Information

Headquarters
825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS, CA, United States 94070
Phone
650-260-7120
Fax
302-697-4597

Executives

Chairman of the Board
Iain Dukes
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Frederick Vogt
Chief Financial Officer
Jean-Marc Bellemin
Chief Operating Officer
Igor Bilinsky
Chief Medical Officer
Friedrich Graf Finckenstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$0.00
Shares Outstanding
157.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.20
EPS
$-2.48
Book Value
$3.96
P/E Ratio
-3.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.